ArticleJournal of virology1996
Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.
Article in Journal of virology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 96 citations in OpenAlex.
- E2A, VA RNA I, and L4-22k adenoviral helper genes are sufficient for AAV production in HEK293 cells.Molecular therapy. Methods & clinical development · 2024Article
- Review
- Review
- Development of a Replication-Deficient Bacteriophage Reporter Lacking an Essential Baseplate Wedge Subunit.Viruses · 2023Article
- Gene Therapy Tools for Brain Diseases.Frontiers in pharmacology · 2019Review
- Article
- NF-κB promotes leaky expression of adenovirus genes in a replication-incompetent adenovirus vector.Scientific reports · 2016Article
- Suppression of leaky expression of adenovirus genes by insertion of microRNA-targeted sequences in the replication-incompetent adenovirus vector genome.Molecular therapy. Methods & clinical development · 2014Article
- Adenoviral producer cells.Viruses · 2010Article
- Adenovirus E1B55K region is required to enhance cyclin E expression for efficient viral DNA replication.Journal of virology · 2008Article
- A helper-dependent capsid-modified adenovirus vector expressing adeno-associated virus rep78 mediates site-specific integration of a 27-kilobase transgene cassette.Journal of virology · 2006Article
- Selective replication of E1B55K-deleted adenoviruses depends on enhanced E1A expression in cancer cells.Cancer gene therapy · 2006Article
- Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.Breast cancer research : BCR · 2005Article
- Adenoviruses as vaccine vectors.Molecular therapy : the journal of the American Society of Gene Therapy · 2004Review
- E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells.Cancer gene therapy · 2004Article
- Role for the adenovirus IVa2 protein in packaging of viral DNA.Journal of virology · 2001Article
- Production of first generation adenovirus vectors: a review.Gene therapy · 2000Review
- Gene therapy in the CNS.Gene therapy · 2000Review
- Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons.Proceedings of the National Academy of Sciences of the United States of America · 1999Article
- Induction of apoptosis and G2/M arrest by infection with replication-deficient adenovirus at high multiplicity of infection.Gene therapy · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Although adenovirus vectors offer many advantages, it would be desirable to develop vectors with improved expression and decreased toxicity. Toward this objective, an adenovirus vector system with deletion of both the El and E2a regions was developed. A 5.9-kb fragment of the adenovirus type 5 (Ad5) genome containing the E2a gene and its early and late promoters was transfected into 293 cells. A complementing cell line, designated 293-C2, expressed the E2a mRNA and protein and was found to complement the defect in Ad5 viruses with temperature-sensitive or deletion mutations in E2a. A deletion of 1.3 kb removing codons 40 to 471 of the 529 amino acids of E2a was introduced into plasmids for preparation of viruses and vectors. An Ad5 virus with disruption of the El gene and deletion of E2a grew on 293-C2 cells but not on 293 cells. Vectors with E1 and E2a deleted expressing Escherichia coli beta-galactosidase or human alpha1-antitrypsin were prepared and expressed the reporter genes after intravenous injection into mice. This vector system retains sequences in common between the complementing cell line and the vectors, including 3.4 kb upstream and 1.1 kb downstream of the deletion. These vectors have potential advantages of increased capacity for insertion of transgene sequences, elimination of expression of E2a, and possibly reduction in expression of other viral proteins. Although the titers of the vectors with deleted are about 10- to 30-fold below those of vectors with E2a wild-type regions, the former vectors are suitable for detailed studies with animals to evaluate the effects on host immune responses, on duration of expression, and on safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.